Moreover, they are unable to recreate pulsatile insulin release, a more effective signal for glucoregulation. 4 Thus, T2D is ideally suited to photopharmacology, which harnesses the precision of light to spatiotemporally deliver drug activity. 5 We have recently shown that a sulfonylurea possessing an azobenzene photoresponsive element (a.k.a. AzoSulfonylurea) can be used to optically control beta cell function and insulin release via its effects on ATP-sensitive potassium (K ATP ) channels and Exchange Protein directly Activated by cAMP 2A (Epac2A) signaling. 6 However, a significant barrier to the use of such 'azo-drugs' for T2D treatment is their ultraviolet-blue absorption spectra, increasing phototoxicity and limiting tissue penetration due to photon scattering. 7 By contrast, visible/near infrared wavelengths demonstrate better penetrance in the body. 8 Spurred on by recent studies of ortho-or para-substituted azobenzenes, [9] [10] [11] we therefore devised a novel approach for the synthesis of wavelength-tuned photopharmaceuticals with red-shifted photochromism. An AzoSulfonylurea based on glimepiride was achieved by installing a heterocyclic aromatic unit, rather than sterically bulky electron-donating halogen or amine moieties (Scheme 1). Starting with the deacetylation of acetazolamide (1) in refluxing HCl, heterocycle 2 was obtained that could be further diazotized with in situ generated HNO 2 . Trapping the resulting diazonium salt with N,N-diethylaniline generated sulfonamide azobenzene 3. Finally, reaction with cyclohexyl isocyanate yielded JB558 via acylation of the sulfonamide, giving unprecedented access to a sulfonylurea containing a heterocyclic azobenzene. While yields were reduced compared to the previously described JB253 (37% versus 97%), 6 this was most likely due to the (4) and insulin secretion (5) . (c) Synthesis of the AzoSulfonylurea JB558 that can be switched from the trans-to the cis-isomer using green/yellow light.
presence of a less reactive sulfonamide intermediate, as predicted by the lower pK a value for 3 (7.36, Fig. S1 , ESI †) and JB558 (2.35, see ESI †). JB558 possessed a red-shifted absorption spectrum (l max = 526 nm) in DMSO (Fig. 1a) , and could be repeatedly photoconverted to its cis-state with green-yellow light (l = 520 nm) (Fig. 1b) . Thermal back relaxation occurred rapidly in the dark and switching kinetics were within the millisecond range (t cis = 64.9 AE 1.5 ms; t trans = 410.8 AE 12.6 ms), without obvious decomposition (Fig. 1b) . JB558 was stable in the presence of Escherichia coli azoreductase, an enzyme expected to limit oral bioavailability through diazene cleavage in the intestine (Fig. S2 , ESI †).
To determine the binding affinity of JB558 to the K ATP channel subunit SUR1, as well as Epac2A, [3H]-glibenclamide displacement and FRET assays were performed. While trans-JB558 bound SUR1 with B10 000-fold less affinity than glimepiride (IC 50 (trans-JB558) = 37.3 mM; IC 50 (Glim) = 1.8 nM) (Fig. 2a) , it was able to strongly and light-dependently activate an Epac2-camps biosensor containing the sulfonylurea binding domain (Fig. 2b-d) . 12 Electrophysiological recordings of K + currents in HEK293T-SUR1-Kir6.2 cells revealed partial K ATP channel blockade by trans-JB558, presumably due to the momentary stationary state favoring some continued cis-isomerization (Fig. S3, ESI †) . We next assessed the photoswitching properties of JB558 in native beta cells where sulfonylurea-mediated K ATP channelEpac2A signaling is intimately linked to voltage-dependent Ca 2+ channel (VDCC) activity and insulin exocytosis. [13] [14] [15] [16] As expected, JB558 was able to evoke large increases in intracellular Ca 2+ concentrations in B60% of beta cells following exposure to yellow (l = 561 AE 5 nm) ( Fig. 3a and b) , but not violet (l = 405 AE 5 nm) light (Fig. 3c) . These effects were potentiated using a high concentration of glimepiride (Fig. 3d) , and abrogated using diazoxide (Fig. 3e) to force open the K ATP channel pore. Repeated switching of cytosolic Ca 2+ concentrations could be achieved in the same islet following a brief period of dark exposure to induce trans-JB558 accumulation (Fig. 3f) . Similar to the results observed in rodent tissue, cis-JB588 was able to confer light-sensitivity on Ca 2+ -spiking activity in human pancreatic islets (Fig. 4a-c) , and this effect could be reversed following 5 min relaxation in the dark (Fig. 4d) .
To link photocontrol of Ca 2+ levels with insulin secretion, batches of rodent islets were incubated with JB558 and exposed to either dark (no illumination) or light (l = 560 AE 10 nm). JB558-treated islets kept under dark conditions were no different to controls (5 mM glucose-alone) (Fig. 5a) , suggesting that the observed stationary state K ATP channel block was insufficient to elicit exocytosis. By contrast, irradiation dramatically stimulated insulin release (Fig. 5a) . Finally, cytotoxicity assays demonstrated that JB558 did not adversely affect cell viability, as assessed using the vital stain calcein and the necrosis indicator propidium iodide (Fig. 5b and c) .
The data presented here outline a synthetic route for the production of AzoSulfonylureas with red-shifted photochromism. Consistent with its sulfonylurea backbone, JB558 was able to bind SUR1 and activate Epac2A. Formation of cis-JB558 occurred with green-yellow light (l = 520-561 nm), and thermal back relaxation in the dark yielded trans-JB558. While photoconversion between cis-and trans-forms was rapid in solution, it was slower in the tissue setting, taking minutes for reisomerization. An effect of Fluo-2 excitation on the isomer equilibrium cannot be excluded, although illumination at l = 491 nm per se was unable to evoke Ca 2+ rises in either Fluo-2-or Fura2 (l = 340 nm/380 nm)-loaded islets (Fig. S4, ESI †) .
A more plausible explanation is the inactivation of beta cell Epac2A-signaling, which may lag behind that of JB558 due to persistent mobilization of intracellular Ca 2+ . 1, 17 Such tissue effects may be desirable for the development of photopharmaceuticals, since pulsed illumination would reduce phototoxicity, while sustaining compound activity to match long-lasting (dozens of minutes) insulin peaks. 4 Indeed, JB558 displayed almost 3-fold more potency than its blue-light activated predecessor JB253, 6 most likely due to slower back-relaxation during the light pulses used in the secretion assays. Neither were we able to detect photoswitching of K + currents in HEK293T cells overexpressing K ATP channels, free from orthogonal wavelengths (Fig. S5, ESI †) . This was likely because HEK293T cells do not express sufficient Epac2A to allow JB558 to properly toggle K ATP activity, 13, 15, 18 and/or the inability to deliver sufficient illumination using the non-coherent source on our patch-clamp setup (e 520nm (JB558) = 1.14 Â 10 5 mol À1 cm
À1
; see ESI †). Nonetheless, we clearly show that JB558 light-dependently binds Epac2A, allowing optical control of cell function and insulin secretion with l = 560 nm in the most physiologically-relevant testbed, viz. the islets of Langerhans. Thus, JB558 represents a blueprint for red-shifted AzoSulfonylureas based upon heterocyclic azobenzenes. Further studies are now warranted to improve isomerization kinetics in tissue to improve the use of JB558 as a research tool for rapid K ATP channel manipulation. Importantly, similar synthetic approaches may also be applicable to other clinically-relevant azobenzene-possessing compounds where steric hindrance may affect molecule motion e.g. neuromodulators, 19 neurotransmitters, 20 
